Mark A. Schroeder, MD, MSCI
- Bone Marrow Transplant
- Cancer (Oncology)
- English
Appointments
Sees Patients For
Oncology, cancer, bone marrow transplant and cellular therapies, multiple myeloma, leukemia, graft-versus-host disease, MDS, transplant biology, stem cell transplant and cellular immunotherapies such as CART, hematologic cancers with a focus in multiple myeloma
Hospital Affiliations
This provider offers inpatient care at these hospitals.
- Barnes-Jewish Hospital
Locations
- Siteman Cancer Center at 4500 Forest Park Avenue4500 Forest Park AvenueSt. Louis, MO 63108Appointments:
- Barnes-Jewish Hospital1 Barnes Jewish Hospital PlazaSt. Louis, MO 63110
Experience
Board Certifications
- Medical Oncology
- Hematology
Academic Title(s)
Professor, MedicineDivision of Oncology
Section of Blood and Marrow Transplant
Research Interests
Dr. Schroeder has a translational research focus in transplant biology and the development of novel therapeutics and treatment approaches for multiple myeloma and graft-versus-host disease. His research in transplant biology includes improving stem cell mobilization; understanding and improving treatment of graft-versus-host disease and novel cellular and immunotherapies for myeloma. His clinical research interest includes hematologic malignancies, such as myeloma, MDS, AML, and CLL; and, their treatment by hematopoietic stem cell transplantation and the development of new treatment approaches.
Publications & Research
View research profile »Education
1999 University of Toledo, Toledo, OH
2003 University of Cincinnati, College of Medicine, Cincinnati, Ohio
2006 Barnes Jewish Hospital, St. Louis, MO
2009 Washington University School of Medicine, St. Louis, MO
2012 Washington University School of Medicine, St. Louis, MO
- GlaxoSmithKline-Parexel
- Consulting/Advisory Board: $100,000 - $149,999
- Reporting Date: 05/01/2024
- NovoNordisk - IQVIA RDS
- Consulting/Advisory Board: $10,000 - $19,999
- Reporting Date: 05/01/2024
Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.